Inverse prognostic impact of ErbB2 mRNA and protein expression level in tumors of soft tissue sarcoma patients;Inverse Korrelation von ErbB2-mRNA und der Proteinexpression in Weichteilsarkompatienten

Strahlentherapie und Onkologie

Volumn 190, Issue 10, 2014, Pages 912-918

  Wichmann, Henri ^a   Güttler, Antje ^a   Bache, Matthias ^a   Taubert, Helge ^b   Vetter, Martina ^a   Würl, Peter ^c   Holzhausen, Hans J ^a   Eckert, Alexander W ^a   Kappler, Matthias ^a   Vordermark, Dirk ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c Diakoniekrankenhaus Halle   (Germany)

Author keywords

Biological marker; HER2; Human epidermal growth factor receptor 2; Prognosis; Treatment outcome

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; ERBB2 PROTEIN, HUMAN; MICRORNA; TUMOR MARKER;

ABDOMEN; ADULT; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CANCER TISSUE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE SEVERITY; DISTANT METASTASIS; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FIBROSARCOMA; GENE EXPRESSION; HEAD; HUMAN; LIMB; LIPOSARCOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; SOFT TISSUE SARCOMA; THORAX; AGED; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; EPIDEMIOLOGY; GENETICS; GERMANY; METABOLISM; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PREVALENCE; PROGNOSIS; PROTO ONCOGENE; REPRODUCIBILITY; RISK FACTOR; SARCOMA; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENES, ERBB-2; GERMANY; HUMANS; MALE; MICRORNAS; NEOPLASM RECURRENCE, LOCAL; PREVALENCE; PROGNOSIS; RADIOTHERAPY, CONFORMAL; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SARCOMA; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84919846112     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-014-0655-8     Document Type: Article

References (40)

1. Greve B, Sheikh-Mounessi F, Kemper B et al (2012) Survivin, a target to modulate the radiosensitivity of Ewing’s sarcoma. Strahlenther Onkol 188:1038–1047
2. Eckert F, Gani C, Kluba T et al (2013) Effect of concurrent chemotherapy and hyperthermia on outcome of preoperative radiotherapy of high-risk soft tissue sarcomas. Strahlenther Onkol 189:482–485
3. Enzinger FM, Weiss SW (1995) Soft tissue tumours. Mosby, St. Louis
4. Guillou L, Coindre JM, Bonichon F et al (1997) Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 15:350–362
5. Moasser MM (2007) The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26:6469–6487
6. Kasprzyk PG, Song SU, Difiore PP et al (1992) Therapy of an animal-model of human gastric-cancer using a combination of anti-ErbB-2 monoclonal-antibodies. Cancer Res 52: 2771–2776
7. Sauer G, Deissler H, Kurzeder C et al (2002) New molecular targets of breast cancer therapy. Strahlenther Onkol 178:123–133
8. Olayioye MA (2001) Update on HER-2 as a target for cancer therapy—intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res 3:385–389
9. Guo GZ, Wang TL, Gao Q et al (2004) Expression of ErbB2 enhances radiation-induced NF-kappa B activation. Oncogene 23:535–545
10. Fehm T, Maul H, Gebauer S et al (2005) Prediction of axillary lymph node status of breast cancer patients by tumorbiological factors of the primary tumor. Strahlenther Onkol 181:580–586
11. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127–137
12. Karunagaran D, Tzahar E, Beerli RR et al (1996) ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 15:254–264
13. Tzahar E, Waterman H, Chen XM et al (1996) A hierarchical network of interreceptor interactions determines signal transduction by neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16:5276–5287
14. GrausPorta D, Beerli RR, Daly JM et al (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16:1647–1655
15. Murphy CG, Morris PG (2012) Recent advances in novel targeted therapies for HER2-positive breast cancer. Anticancer Drugs 23:765–776
16. Foster H, Knox S, Ganti AK et al (2003) HER-2/neu overexpression detected by immunohistochemistry in soft tissue sarcomas. Am J Clin Oncol-Canc 26:188–191
17. Sato T, Peiper M, Heinecke A et al (2003) Expression of HER2/neu does not correlate with survival in soft tissue sarcoma. Onkologie 26:268–271
18. Potti A, Ganti AK, Foster H et al (2004) Immunohistochemical detection of HER-2/neu, c-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas. Anticancer Res 24:333–337
19. Nuciforo PG, Pellegrini C, Fasani R et al (2003) Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma. Hum Pathol 34:639–645
20. Wurl P, Kappler M, Meye A et al (2002) Co-expression of survivin and TERT and risk of tumour-related death in patients with soft tissue sarcoma. Lancet 359:943–945
21. Taubert H, Greither T, Kaushal D et al (2007) Expression of the stem cell self-renewal gene Hiwi and risk of tumour-related death in patients with soft tissue sarcoma. Oncogene 26:1098–1100
22. Hahnel A, Wichmann H, Kappler M et al (2010) Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells. Radiation Oncology 5:82
23. Muller V, Thomssen C, Karakas C et al (2003) Quantitative assessment of HER-2/neu protein concentration in breast cancer by enzyme-linked immunosorbent assay. Int J Biol Markers 18:13–20
24. Hernan R, Fasheh R, Calabrese C et al (2003) ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res 63:140–148
25. Verbeek BS, Adriaansen-Slot SS, Vroom TM et al (1998) Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. FEBS Lett 425:145–150
26. Zafrakas M, Zepiridis L, Theodoridis TD et al (2009) ErbB2 (HER2) protein expression in uterine sarcomas. Eur J Gynaecol Oncol 30:292–294
27. Amant F, Vloeberghs V, Woestenborghs H et al (2004) ErbB-2 gene overexpression and amplification in uterine sarcomas. Gynecol Oncol 95:583–587
28. George E, Niehans GA, Swanson PE et al (1992) Overexpression of the C-ErbB-2 oncogene in sarcomas and small round-cell tumors of childhood—an immunohistochemical investigation. Arch Pathol Lab Med 116:1033–1035
29. Thomas DG, Giordano TJ, Sanders D et al (2005) Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer 103:830–838
30. Andrade CR, Takahama JA, Nishimoto IN et al (2010) Rhabdomyosarcoma of the head and neck: a clinicopathological and immunohistochemical analysis of 29 cases. Braz Dent J 21:68–73
31. Krskova L, Kalinova M, Brizova H et al (2007) Molecular and immunohistochemical analysis of ERBB2 expression in correlation with proliferation rate. in synovial sarcoma. Diagn Mol Pathol 16:211–217
32. Akatsuka T, Wada T, Kokai Y et al (2002) ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 94:1397–1404
33. Ljuslinder I, Malmer B, Golovleva I et al (2005) Increased copy number at 3p14 in breast cancer. Breast Cancer Res 7:R719–R727
34. Underwood M, Bartlett J, Reeves J et al (1995) C-Erbb-2 gene amplification—a molecular marker in recurrent bladder-tumors. Cancer Res 55:2422–2430
35. Haugen DRF, Akslen LA, Varhaug JE et al (1992) Expression of C-Erbb-2 protein in papillary thyroid carcinomas. Br J Cancer 65:832–837
36. Gonzalez-Angulo AM, Litton JK, Broglio KR et al (2009) High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27:5700–5706
37. Cao N, Li SY, Wang ZQ et al (2009) NF-kappa B-mediated HER2 overexpression in radiation-adaptive resistance. Radiat Res 171:9–21
38. Akatsuka T, Wada T, Kokai Y et al (2001) Loss of ErbB2 expression in pulmonary metastatic lesions in osteosarcoma. Oncology 60:361–366
39. Dawood S, Broglio K, Esteva FJ et al (2008) Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 19:1242–1248
40. Mittra I, Redkar AA, Badwe RA (1995) Prognosis of breast-cancer—evidence for interaction between C-ErbB-2 overexpression and number of involved axillary lymph-nodes. J Surg Oncol 60:106–111